Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BEVC is an early-stage venture capital firm located in Berkeley, California. Founded by a team of investors and scientists, the firm is embedded in the innovation ecosystem of Berkeley and UCSF. It focuses on transforming scientific advancements into disruptive companies, managing a portfolio of 8 companies.
BEVC invests in early-stage companies at the Pre-Seed, Seed, and Series A stages, primarily in the healthcare and energy sectors. The firm targets transformational technology with high impact potential, emphasizing the intersection of science, computation, and engineering. Its geographical focus is on the San Francisco Bay Area.
Notable portfolio companies include Addition Therapeutics, which develops RNA-only genetic medicines; AIMATX, utilizing AI for breakthrough materials; Dextera Biosciences, focusing on synthetic D-protein drugs; Insamo Therapeutics, working on oral macrocyclic peptide drugs; Khemia Metals, aiming to create sustainable batteries; Montara Therapeutics, developing therapies for neurological diseases; PinkDx, engaged in non-invasive diagnostics for women’s health; and Radar Therapeutics, focusing on precision therapeutics using smart mRNA logic.
Submit your pitch through their website contact form for consideration.
Yes, BEVC often leads investment rounds in the companies they back, particularly in the early stages.
BEVC is open to follow-on investments, especially if the company demonstrates significant progress and potential for growth.
Specific fund size details are not disclosed, but BEVC focuses on early-stage investments across its portfolio.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.